Alexion Pharmaceuticals, Inc. reported consolidated unaudited earnings results for the first quarter ended March 31, 2013. For the period, the company reported net product sales were $338,941,000 against $244,733,000 a year ago. Operating income was $116,972,000 against $70,038,000 a year ago. Income before income taxes was $116,741,000 against $67,809,000 a year ago. Net income was $82,217,000 against $45,413,000 a year ago. Diluted per share was $0.41 against $0.23 a year ago. Non-GAAP net income was $131,314,000 against $88,061,000 a year ago. Non-GAAP earnings per share – diluted was $0.65 against $0.45 a year ago. Alexion announced that it is raising its 2013 revenue guidance from the previous range of $1.490 to $1.505 billion, now to the higher range of $1.505 to $1.520 billion. The upward revision reflects continued global growth of Soliris in PNH and growth from the ongoing launch of Soliris in aHUS. Guidance for 2013 non-GAAP earnings per share is also being raised, from the previous range of $2.82 to $2.92, now to the higher range of $2.87 to $2.97 per share. The gross margin to be 10%.

Alexion Pharmaceuticals, Inc. announced that it is broadening and strengthening its executive leadership team in line with the company's expanding global mission to develop and commercialize life transforming therapies for patients with disorders that are severe, life-threatening, and ultra-rare. Stephen Squinto, Ph.D., co-founder of Alexion, is being promoted to the newly created position of Executive Vice President, Chief Global Operations Officer. Martin Mackay, Ph.D. will be joining Alexion as Executive Vice President, Global Head of R&D, and Saqib Islam, J.D. has joined Alexion as Senior Vice President, Chief Strategy and Portfolio Officer. All three executives will report directly to Leonard Bell, M.D., Chief Executive Officer of Alexion. The arrivals of Dr. Mackay and Mr. Islam will help to broaden Alexion's portfolio of transformative ultra-orphan therapeutic candidates and accelerate the development of these candidates into approved products. The promotion of Dr. Squinto to his new position will support these initiatives, and also improve and expand critical processes in manufacturing, quality and corporate project management. Most recently, Dr. Squinto has driven the expansion of Alexion's R&D pipeline to now comprise five highly innovative therapeutic candidates. In his new position of Chief Global Operations Officer, Dr. Squinto will increasingly focus his activities on leadership of the Company's critical technical operations and quality organizations. Dr. Squinto will commence his new duties at Alexion in mid-May. Most recently, Dr. Mackay served as President, Research and Development at AstraZeneca, reporting directly to the CEO, where he led all R&D functions on a global basis, including discovery research, clinical development, regulatory affairs and key related R&D functions. Dr. Mackay will join Alexion in mid-May. Mr. Islam brings to Alexion 18 years of experience in global business management, with a focus on business development, strategic decision-making and planning, and capital markets. In his new position, he will focus on both executing corporate growth strategies as well as contributing to assessment and management of global operations. Mr. Islam has an extensive background in the healthcare banking sector, having held positions of increasing responsibility in the investment banking divisions of Merrill Lynch, Morgan Stanley, and most recently, Credit Suisse Securities, where he served as Managing Director, Head of Healthcare and Diversified Industrials Capital Markets.

Alexion Pharmaceuticals, Inc., Annual General Meeting, May 06, 2013., at 17:00 US Eastern Standard Time. Location: Yale, 1157 Chapel Street. Agenda: To elect nine directors to Alexion's Board of Directors, constituting the entire Board, to serve for the ensuing year; to consider a non-binding advisory vote on 2012 compensation paid to Alexion's named executive officers; to approve Alexion's Amended and Restated 2004 Incentive Plan, including an amendment to increase the number of shares of common stock available for issuance by 12 million shares (subject to adjustment in the event of stock splits and other similar events); to ratify the appointment of PricewaterhouseCoopers LLP as Alexion's independent registered public accounting firm; and to transact such other business as may properly come before the 2013 Annual Meeting or any adjournment thereof.